The Atrial Fibrillation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atrial Fibrillation pipeline products will significantly revolutionize the Atrial Fibrillation market dynamics.
DelveInsight’s “Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Atrial Fibrillation market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Atrial Fibrillation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atrial Fibrillation Market Insights
Some of the key facts of the Atrial Fibrillation Market Report:
-
The Atrial Fibrillation market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
-
In October 2025, Pulse Biosciences, Inc. (NASDAQ: PLSE) is pioneering bioelectric medicine using its proprietary Nano-Pulse Stimulation (NPS) technology, focusing on immuno-oncology, dermatology, and cardiac ablation. Its Nanosecond Pulsed Field Ablation (nsPFA) system provides non-thermal cellular treatment methods and has received FDA Breakthrough Device Designation for its potential to revolutionize cardiac therapy.
-
In October 2025, Kardium, a private medical device company focused on transforming atrial fibrillation (AF) treatment, announced the successful completion of its first commercial procedures using the Globe Pulsed Field System, its integrated mapping and ablation platform, following recent FDA approval.
-
In July 2025, DeepQure announced that South Korea’s Ministry of Food and Drug Safety (MFDS) has granted approval for a clinical trial of its HyperQure™ RDM System, an innovative laparoscopic renal denervation (RDN) technology, for treating atrial fibrillation (AF). The study aims to assess the safety and effectiveness of laparoscopic RDN in patients with recurrent AF after pulmonary vein isolation (PVI) and those with resistant hypertension. Designed as a multicenter, prospective, single-arm, open-label exploratory trial, it will provide key insights into the potential of this novel approach.
-
In March 2025, At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, Fretz et al. presented findings from a study examining the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on atrial fibrillation (AF) occurrence after hospitalisation for heart failure (HF). The onset of AF in HF patients is linked to higher morbidity and mortality rates. While GLP-1RA therapies have been shown to lower cardiovascular (CV) risk and enhance outcomes in patients with preserved-ejection fraction HF, their influence on AF incidence in HF populations has not yet been fully established.
-
In January 2025, The initial phase of the ADVANTAGE AF clinical trial successfully met its safety and efficacy endpoints for treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSE™ Pulsed Field Ablation System. Additionally, a sub-analysis from the OPTION clinical trial demonstrated consistent safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device when used after cardiac ablation, whether performed simultaneously (concomitant) or separately (sequential).
-
In January 2025, CardioFocus, Inc., a medical device company specializing in ablation therapies for cardiac arrhythmias, has shared the 12-month outcomes from its ECLIPSE AF trial, published in Circulation: Arrhythmia & Electrophysiology. The study demonstrated that 90.2% of patients with paroxysmal atrial fibrillation (AF) remained free from clinically significant atrial arrhythmias one year after undergoing de novo pulmonary vein isolation (PVI). This result was achieved through the use of three commercially available contact-force sensing focal catheters in combination with the Centauri™ System’s advanced WAVE1™ pulsed field ablation (PFA) waveform.
-
In January 2025, Boston Scientific Corporation (NYSE: BSX) has shared new data backing the use of both the FARAPULSE™ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device at the AF Symposium 2025 during a late-breaking science session. The session also featured a predefined sub-analysis from the OPTION clinical trial, which expanded on the favorable primary endpoint outcomes previously presented at the American Heart Association 2024 conference and published in The New England Journal of Medicine. The analysis involved 1,600 atrial fibrillation patients who received device implantation either at the time of ablation or 90–180 days later, supporting the 36-month findings comparing the WATCHMAN FLX with direct oral anticoagulants (mostly DOACs)
-
In January 2025, The initial phase of the ADVANTAGE AF clinical trial has achieved its safety and efficacy goals in treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSE™ Pulsed Field Ablation (PFA) System. While the FARAPULSE PFA System is currently approved for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation—where irregular heart rhythms occur intermittently and typically resolve on their own—this study assessed its use for both PVI and posterior wall ablation (PWA) in those with persistent atrial fibrillation. This form of AF lasts longer than seven days and represents about 25% of all AF cases. The prospective, single-arm trial included 260 patients across 43 international sites who were unresponsive to at least one Class I or III anti-arrhythmic drug.
-
In October 2024, Abbott has reached two significant milestones in its clinical trials evaluating its pulsed field ablation (PFA) technology for managing irregular heart rhythms. The first milestone involved the early completion of patient enrollment in the VOLT-AF study. Abbott confirmed that enrollment concluded ahead of schedule. This study, conducted under an investigational device exemption (IDE), is designed to assess the effectiveness of Abbott’s VOLT PFA system in treating atrial fibrillation (AF).
-
According to the study conducted by Rosenthal et al. 2016, Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. It affects more than 2.7 to 6.1 million persons in the United States
-
According to a study by Chung et al., 2021, in the UK, there are an estimated 1.5 million individuals living with Atrial Fibrillation, similar to the number of people with MI and exceeding those of cerebrovascular diseases and heart failure in 2020.
-
Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others
-
Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others
-
The Atrial Fibrillation epidemiology based on gender analyzed that Atrial fibrillation affects males more than females
Atrial Fibrillation Overview
Atrial Fibrillation (AF) is an abnormal heart rhythm (arrhythmia) characterized by the rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain.
Get a Free sample for the Atrial Fibrillation Market Report -
https://www.delveinsight.com/report-store/atrial-fibrillation-market
Atrial Fibrillation Market
The dynamics of the Atrial Fibrillation market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Atrial Fibrillation Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Atrial Fibrillation Epidemiology Segmentation:
The Atrial Fibrillation market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Atrial Fibrillation
-
Prevalent Cases of Atrial Fibrillation by severity
-
Gender-specific Prevalence of Atrial Fibrillation
-
Diagnosed Cases of Episodic and Chronic Atrial Fibrillation
Download the report to understand which factors are driving Atrial Fibrillation epidemiology trends @ Atrial Fibrillation Epidemiological Insights
Atrial Fibrillation Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atrial Fibrillation market or expected to get launched during the study period. The analysis covers Atrial Fibrillation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Atrial Fibrillation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Atrial Fibrillation Therapies and Key Companies
-
Research programme: Thryv Therapeutics Inc.
-
CTP-Amio: Vivasc Therapeutics
-
VE 1902: Verseon
-
HBI-3000: HUYA Bioscience
-
HSY 244: Novartis
-
AGN-151607: AbbVie
-
Asundexian: Bayer AG
-
Inrhythm: InCarda Therapeutics, Inc.
To know more about Atrial Fibrillation treatment, visit @ Atrial Fibrillation Medications
Scope of the Atrial Fibrillation Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others
-
Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others
-
Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
-
Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Atrial Fibrillation Unmet Needs, KOL’s views, Analyst’s views, Atrial Fibrillation Market Access and Reimbursement
Discover more about therapies set to grab major Atrial Fibrillation market share @ Atrial Fibrillation Treatment Landscape
Table of Contents
1. Atrial Fibrillation Market Report Introduction
2. Executive Summary for Atrial Fibrillation
3. SWOT analysis of Atrial Fibrillation
4. Atrial Fibrillation Patient Share (%) Overview at a Glance
5. Atrial Fibrillation Market Overview at a Glance
6. Atrial Fibrillation Disease Background and Overview
7. Atrial Fibrillation Epidemiology and Patient Population
8. Country-Specific Patient Population of Atrial Fibrillation
9. Atrial Fibrillation Current Treatment and Medical Practices
10. Atrial Fibrillation Unmet Needs
11. Atrial Fibrillation Emerging Therapies
12. Atrial Fibrillation Market Outlook
13. Country-Wise Atrial Fibrillation Market Analysis (2019–2032)
14. Atrial Fibrillation Market Access and Reimbursement of Therapies
15. Atrial Fibrillation Market Drivers
16. Atrial Fibrillation Market Barriers
17. Atrial Fibrillation Appendix
18. Atrial Fibrillation Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
